Hidradenitis Suppurativa Pipeline Drugs and Companies Insight Report: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

October 21 05:35 2021
Hidradenitis Suppurativa Pipeline Drugs and Companies Insight Report: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments
DelveInsight Business Research LLP
DelveInsight’s ‘Hidradenitis Suppurativa Market Insights, Epidemiology and Market Forecast-2030’ report delivers an in-depth understanding of the Hidradenitis Suppurativa, historical and forecasted epidemiology as well as the Hidradenitis Suppurativa market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom) and Japan.

DelveInsight’s “Hidradenitis Suppurativa Pipeline Insight” report provides comprehensive insights about key companies and pipeline drugs in the Hidradenitis Suppurativa pipeline landscapes. It comprises Hidradenitis Suppurativa pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Hidradenitis Suppurativa therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Hidradenitis Suppurativa pipeline products.     

Some of the key takeaways of the Hidradenitis Suppurativa Pipeline Report  

  • Companies across the globe are diligently working toward the development of novel treatment therapies with a considerable amount of success over the years. Key players, such as InflaRx, Novartis, ChemoCentryx, UCB Biopharma, Janssen Pharmaceutical / XBiotech, Incyte Corporation, etc., are developing therapies for the treatment of Hidradenitis Suppurativa.

  • Emerging therapies such as IFX-1, CJM112, Cosentyx (Secukinumab), INCB054707, Bimekizumab, Bermekimab (MABp1), Avacopan, are expected to have a significant impact on the Hidradenitis Suppurativa market in the coming years.

Get an overview of pipeline landscape @ Hidradenitis Suppurativa Clinical Trials Analysis 

Hidradenitis Suppurativa Overview

Hidradenitis Suppurativa (HS) is a complex dermatological disease characterized by recurrent painful nodules and suppuration in areas such as the axilla and groin. It is also known as Acne inversa and there is no biological or pathological test to facilitate diagnosis, it can be defined by its clinical features and its chronicity. 

Hidradenitis Suppurativa Emerging Drugs

  1. IFX-1: InflaRx

  2. Cosentyx/Secukinumab: Novartis

  3. Avacopan: ChemoCentryx

  4. Bimekizumab: UCB Biopharma

  5. Bermekimab (MABp1): Janssen Pharmaceutica l / XBiotech

  6. INCB054707: Incyte Corporation

For further information, refer to the detailed report @ Hidradenitis Suppurativa Pipeline Therapeutics 

Scope of Hidradenitis Suppurativa Pipeline Drug Insight    

  • Coverage: Global 

  • Major Players: InflaRx, Novartis Pharmaceuticals, Incyte Corporation, UCB Biopharma S.P.R.L., Janssen Pharmaceutical, Pfizer, and others.

  • Pipeline Therapies: IFX-1, Cosentyx (Secukinumab), INCB054707, Bimekizumab, Bermekimab (MABp1), Avacopan, and others.

Table of Contents


Hidradenitis Suppurativa Report Introduction


Hidradenitis Suppurativa Executive Summary


Hidradenitis Suppurativa Overview


Hidradenitis Suppurativa- Analytical Perspective In-depth Commercial Assessment


Hidradenitis Suppurativa Pipeline Therapeutics


Hidradenitis Suppurativa Late Stage Products (Phase II/III)


Hidradenitis Suppurativa Mid Stage Products (Phase II)


Hidradenitis Suppurativa Early Stage Products (Phase I)


Hidradenitis Suppurativa Preclinical Stage Products


Hidradenitis Suppurativa Therapeutics Assessment


Hidradenitis Suppurativa Inactive Products


Company-University Collaborations (Licensing/Partnering) Analysis


Hidradenitis Suppurativa Key Companies


Hidradenitis Suppurativa Key Products


Hidradenitis Suppurativa Unmet Needs


Hidradenitis Suppurativa Market Drivers and Barriers


Hidradenitis Suppurativa Future Perspectives and Conclusion


Hidradenitis Suppurativa Analyst Views




About DelveInsight

Get a customized pipeline report @ Hidradenitis Suppurativa Drugs Pipeline Report.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/